Clinical trials: Wart
Warts
The Purpose of This Study is to Determine Whether Topical Application of PEP005 is Safe for the Treatment of Common Wart(s)
Verruca vulgaris, otherwise known as the common wart, is caused by the human papillomavirus (HPV). Common warts are generally located on the hands and feet, but can also occur elsewhere (e.g., any areas of frequent contact).
- Trial name
- NCT00546611
- Testing
- PEP005
- Where
- Australia
- Sponsor
- Peplin
Penile Cancer, Anal Cancer
Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old
To evaluate the safety and tolerability of the 9vHPV vaccine in Chinese healthy male aged 9 to 45 years.
- Conditions
- Penile Cancer, Anal Cancer, PIN-1, PIN-2
- Trial name
- NCT05518201
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Genital Warts, Perianal Warts
Pharmacokinetic Study of Topically Applied Veregen 15% Compared With Oral Intake of Green Tea Beverage
This open, monocentric study is designed to investigate plasma concentrations of certain catechins after topical application of Veregen 15% ointment to genital or perianal warts in comparison to catechin plasma concentrations…
- Trial name
- NCT01082302
- Testing
- Polyphenon E (Veregen) 15% ointment, Green Tea Beverage with defined catechin content
- Where
- Germany
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- MediGene
External Genital Warts
Efficacy and Tolerability of Topical LFX453 for External Genital Warts
The LFX453X2202 study tested the investigational drug LFX453 against placebo for safety, tolerability, and efficacy in treating genital warts in circumcised men, in parallel with an additional open label arm using imiquimod 5%.
- Trial name
- NCT02482428
- Testing
- Investigational Treatment, Aldara
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- Novartis Pharmaceuticals
Common Wart, Flat Wart
Randomized, Placebo-controlled, Double Blind Study to Evaluate the Efficacy of 2LVERU®JUNIOR and 2LVERU® on the Treatment of Warts
Human papillomavirus (HPV) infection is very common, as most people will experience infection during their lifetime. The most common manifestation of HPV infection is common warts. Common warts may appear at any age.
- Conditions
- Common Wart, Flat Wart, Plantar Wart
- Trial name
- EVAsION (NCT03977753)
- Testing
- 2LVERU® or 2LVERU® JUNIOR
- Where
- 6 sites in Belgium
- Volunteers
- 162 people
- Sponsor
- Labo'Life
Recurrent Condyloma, Nonrecurrent Condyloma
Recurrent and Nonrecurrent Condyloma Treatment
Treatment is considered successful if the difference in the response in the reduction of the affected area is above 30% for any of the doses compared to placebo Patients will be randomised to 1 of 3 treatment arms 1. Placebo 2.
- Trial name
- NCT01639638
- Testing
- PROAPOPTOTIC PEPTIDE CIGB 300
- Where
- Argentina
- Volunteers
- 132 people
- Sponsor
- Laboratorio Elea Phoenix S.A.
Cervical Cancer, Genital Warts
Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)
The primary purpose of the study is to determine if GARDASIL (V501) with four components is able to prevent cervical cancer, cervical dysplasia, including Cervical Intraepithelial Neoplasia (CIN)(Any Grade) and Adenocarcinoma In…
- Trial name
- NCT00092521
- Testing
- V501, Human Papillomavirus (HPV) 16 Monovalent
- Volunteers
- 5,759 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Genital Warts, Anal Cancer
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003)
This study is designed to evaluate the immunogenicity and tolerability of 9vHPV (9-valent HPV vaccine, V503) in 16- to 26-year old men and women.
- Conditions
- Genital Warts, Anal Cancer, Anal Intraepithelial Neoplasia
- Trial name
- NCT01651949
- Testing
- 9vHPV Vaccine
- Volunteers
- 2,520 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Common Warts
Active-Controlled Study to Assess the Efficacy and Safety of DFD-05 in Subjects With Common Warts
DFD05 vs. Active01 in the treatment of common warts
- Trial name
- NCT02798419
- Testing
- DFD05 Cream, Active01 Cream
- Where
- 12 sites in United States
- Volunteers
- 50 people
- Sponsor
- Dr. Reddys Laboratories, SA
Verruca, Plantar Wart
Safety & Performance Study of Verruca Treatment Device
This is a non comparative pre-CE marking pilot clinical investigation is required to evaluate the safety and performance in intended use of the Verruca treatment - NPD396, Class IIa medical device for verrucas in the adult…
- Trial name
- NCT01536834
- Testing
- Medical Device
- Where
- United Kingdom
- Volunteers
- 35 people
- Sponsor
- Reckitt Benckiser LLC
Cervical Cancer, Genital Warts
Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)
The purpose of the study is to determine if an investigational vaccine with a single component develops an immune response that is similar to the equivalent investigational vaccine with four components to reduce cervical disease.
- Trial name
- NCT00092482
- Testing
- V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine / Duration of Treatment: 4 years
- Volunteers
- 3,882 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HPV Infections
A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine
A randomized, double-blind and placebo-controlled phase I study to evaluate the safety and immunogenicity of a 9-valent Human Papillomavirus (HPV) vaccine, administered intramuscularly according to a 0, 2, 6-month schedule in 9…
- Trial name
- NCT03900572
- Testing
- HPV Vaccine
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
Wart; External Genital Organs, Condyloma Acuminata
Safety and Efficacy Study to Test Topical AS101 for External Genital Warts
The purpose of this study is to determine whether the improved topical ointment formulation, AS101, is safe and effective in the treatment of external genital warts in females.
- Trial name
- NCT01555112
- Testing
- Topical AS101
- Where
- Israel
- Volunteers
- 12 people
- Sponsor
- BioMAS Ltd
Common Wart, Plantar Wart
Safety & Effectiveness of Wortie Freeze Plus in Common and Plantar Warts
This is a Post-Market clinical Follow-up investigation to evaluate the safety and performed of the medical device Wortie Freeze Plus in the treatment of common and plantar warts.
- Trial name
- NCT05115669
- Testing
- Wortie freeze plus
- Where
- Poland
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Karo Pharma AB
Condyloma
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients
This is a double-blind placebo controlled, randomized, phase 2 study to assess the safety, tolerability, pharmacokinetics and efficacy of twice daily topical applications of AP611074 5% Gel for up to 16 weeks in condyloma patients
- Trial name
- NCT02724254
- Testing
- AP611074 5% gel
- Where
- 12 sites in Argentina, Chile and 2 more
- Volunteers
- 218 people
- Sponsor
- Vaxart
Papillomavirus Infections, Uterine Cervical Neoplasms
Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)
This study will evaluate the safety and immunogenicity of V503 (GARDASIL™9, 9vHPV vaccine) administered to 9- to 26-year-old females and males in Vietnam.
- Conditions
- Papillomavirus Infections, Uterine Cervical Neoplasms, Vulvar Neoplasms, Vaginal Neoplasms
- Trial name
- NCT03546842
- Testing
- 9vHPV vaccine
- Where
- Vietnam
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cervical Cancer, Vulvar Cancer
Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021)
Protocol V503-021 is a long-term follow-up study of the V503-001 base study (NCT00543543) to evaluate the safety, immunogenicity, and long-term effectiveness of V503 vaccine in preventing cervical cancer and related precancers…
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, Genital Warts
- Trial name
- NCT02653118
- Testing
- V503, GARDASIL
- Volunteers
- 4,453 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Genital Wart, Penile Cancer
A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males
This study is designed to evaluate the vaccine efficacy, immunogenicity and safety of the 9-valent (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Human Papillomavirus (HPV) Recombinant Vaccine (Hansenula Polymorpha) in Chinese male…
- Conditions
- Genital Wart, Penile Cancer, Anal Cancer, PIN-1
- Trial name
- NCT06465914
- Testing
- 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Hansenula Polymorpha)
- Where
- 5 sites in China
- Volunteers
- 9,000 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Warts
Imiquimod 5% Cream in the Treatment of External Genital or Perianal Warts in HIV+ Patients
Imiquimod 5% cream in the treatment of external genital or perianal warts in HIV+ patients
- Trial name
- NCT00761371
- Testing
- Imiquimod 5% cream
- Where
- 18 sites in Belgium, France
- Volunteers
- 52 people
- Sponsor
- MEDA Pharma GmbH & Co. KG
Cutaneous Warts
First-in-Human Study of CLS003 ICVT in Subjects With Cutaneous Warts
This phase I/IIa study has an open-label, First-in-Human (FIH), single center design to assess the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of multiple doses of topically applied CLS003 in healthy subjects with…
- Trial name
- NCT02106260
- Testing
- CLS003
- Where
- Netherlands
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Maruho Co., Ltd.